Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
作者信息
Rappaport Stephen H, Clark Jenna M, Delibert Samantha, Maynard Kaylee M, Prasad Paritosh, Kaufman David C, Pietropaoli Anthony P, Quill Caroline M, Groth Christine M
机构信息
University of Rochester Medical Center Rochester, New York.
出版信息
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE.
Abstract
摘要
相似文献
1
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE.
2
Reply to Rappaport : Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE.
3
Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism.
Eur J Intern Med. 2021 Jun;88:141-143. doi: 10.1016/j.ejim.2021.03.025. Epub 2021 Mar 26.
4
[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].
Medicina (B Aires). 2020;80 Suppl 3:65-66.
5
Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey.
Br J Anaesth. 2021 Oct;127(4):e143-e145. doi: 10.1016/j.bja.2021.06.041. Epub 2021 Jul 9.
6
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate.
Medicina (Kaunas). 2020 Sep 27;56(10):506. doi: 10.3390/medicina56100506.
7
A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19.
Br J Hosp Med (Lond). 2020 May 2;81(5):1-2. doi: 10.12968/hmed.2020.0210. Epub 2020 May 18.
8
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15.
9
In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis.
Thromb Res. 2021 Jul;203:82-84. doi: 10.1016/j.thromres.2021.04.026. Epub 2021 May 1.
10
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19.
JAMA. 2021 Apr 27;325(16):1613-1615. doi: 10.1001/jama.2021.4295.
引用本文的文献
1
Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221116350. doi: 10.1177/10760296221116350.
本文引用的文献
1
Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?
Am J Respir Crit Care Med. 2020 Aug 1;202(3):455-457. doi: 10.1164/rccm.202005-1654LE.
2
Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.
Crit Care Med. 2020 Sep;48(9):e783-e790. doi: 10.1097/CCM.0000000000004466.
3
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
J Thromb Haemost. 2020 Aug;18(8):1859-1865. doi: 10.1111/jth.14929.
4
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum.
J Thromb Thrombolysis. 2020 Jul;50(1):72-81. doi: 10.1007/s11239-020-02138-z.
5
COVID-19 update: Covid-19-associated coagulopathy.
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
6
Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines.
J Thromb Thrombolysis. 2020 Jul;50(1):68-71. doi: 10.1007/s11239-020-02125-4.
7
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.
8
Anti-Xa assays: What is their role today in antithrombotic therapy?
Cleve Clin J Med. 2019 Jun;86(6):417-425. doi: 10.3949/ccjm.86a.18029.
9
If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
J Trauma Acute Care Surg. 2016 Dec;81(6):1095-1100. doi: 10.1097/TA.0000000000001142.
10
The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.
Hematol Rep. 2015 Nov 23;7(4):5844. doi: 10.4081/hr.2015.5844.
Zotero 插件